Mink Historical Financial Ratios

INKT Stock

USD 0.69 0.01 1.47%

Mink Therapeutics is lately reporting on over 90 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 0.0 or Invested Capital of 0.0 will help investors to properly organize and evaluate Mink Therapeutics financial condition quickly.

Quick Ratio Current Ratio

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Mink Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

For more information on how to buy Mink Stock please use our How to Invest in Mink Therapeutics guide.

About Mink Financial Ratios Analysis

Mink TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Mink Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Mink financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Mink Therapeutics history.

Mink Therapeutics Financial Ratios Chart

At this time, Mink Therapeutics' Days Payables Outstanding is comparatively stable compared to the past year. Net Debt To EBITDA is likely to gain to 0.16 in 2024, despite the fact that Free Cash Flow Yield is likely to grow to (0.41).

Price To Sales Ratio Days Sales Outstanding Book Value Per Share Ev To Sales Inventory Turnover Net Income Per Share

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Mink Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Mink Therapeutics sales, a figure that is much harder to manipulate than other Mink Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Book Value Per Share

The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Inventory Turnover

A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.

Most ratios from Mink Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Mink Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Mink Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

For more information on how to buy Mink Stock please use our How to Invest in Mink Therapeutics guide.At this time, Mink Therapeutics' Days Payables Outstanding is comparatively stable compared to the past year. Net Debt To EBITDA is likely to gain to 0.16 in 2024, despite the fact that Free Cash Flow Yield is likely to grow to (0.41).

	2021	2023	2024 (projected)
Payables Turnover	9.5K	0.0523	0.0497
Days Of Inventory On Hand	2.3E-5	2.6E-5	2.5E-5

Payables Turnover Days Of Inventory On Hand

Mink Therapeutics fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Average Payables	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Average Inventory	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow
Price To Sales Ratio		0.3	-0.6	0.69	-0.19	-0.59	0.99	0.3	1.0	-0.25	-0.33	-0.85	-0.77	0.85	-0.53	0.71	1.0	-0.6	-0.52	0.68	-0.93	-0.51	0.83	0.46	-0.37	-0.52
Ptb Ratio	0.3		-0.34	0.18	0.53	-0.52	0.27	1.0	0.3	0.51	-1.0	-0.39	0.04	0.37	-0.37	0.49	0.3	-0.31	-0.35	0.44	-0.22	-0.35	0.48	-0.32	-1.0	-0.35
Book Value Per Share	-0.6	-0.34		-0.45	-0.29	0.41	-0.54	-0.34	-0.6	-0.26	0.37	0.86	0.04	-0.84	0.9	-0.46	-0.6	0.91	0.77	-0.44	0.4	0.77	-0.92	-0.37	0.4	0.81
Free Cash Flow Yield	0.69	0.18	-0.45		0.34	-0.76	0.76	0.18	0.69	0.27	-0.21	-0.81	-0.3	0.83	-0.09	0.94	0.69	-0.16	-0.83	0.96	-0.85	-0.83	0.68	0.04	-0.24	-0.81
Operating Cash Flow Per Share	-0.19	0.53	-0.29	0.34		-0.39	-0.16	0.53	-0.19	1.0	-0.53	-0.27	0.71	0.27	-0.02	0.46	-0.19	0.04	-0.65	0.47	0.1	-0.66	0.26	-0.53	-0.52	-0.64
Average Payables	-0.59	-0.52	0.41	-0.76	-0.39		-0.63	-0.52	-0.59	-0.34	0.54	0.67	0.25	-0.69	0.18	-0.83	-0.59	0.2	0.68	-0.84	0.67	0.68	-0.64	0.41	0.57	0.66
Capex To Depreciation	0.99	0.27	-0.54	0.76	-0.16	-0.63		0.27	0.99	-0.22	-0.3	-0.84	-0.77	0.85	-0.43	0.77	0.99	-0.51	-0.54	0.74	-0.97	-0.53	0.8	0.41	-0.34	-0.54
Pb Ratio	0.3	1.0	-0.34	0.18	0.53	-0.52	0.27		0.3	0.51	-1.0	-0.39	0.04	0.37	-0.37	0.49	0.3	-0.31	-0.35	0.44	-0.22	-0.35	0.48	-0.32	-1.0	-0.35
Ev To Sales	1.0	0.3	-0.6	0.69	-0.19	-0.59	0.99	0.3		-0.25	-0.33	-0.85	-0.77	0.85	-0.53	0.71	1.0	-0.6	-0.52	0.68	-0.93	-0.51	0.83	0.46	-0.37	-0.52
Free Cash Flow Per Share	-0.25	0.51	-0.26	0.27	1.0	-0.34	-0.22	0.51	-0.25		-0.51	-0.21	0.76	0.21	-0.01	0.4	-0.25	0.06	-0.6	0.41	0.17	-0.61	0.21	-0.55	-0.5	-0.59
Roic	-0.33	-1.0	0.37	-0.21	-0.53	0.54	-0.3	-1.0	-0.33	-0.51		0.42	-0.02	-0.4	0.4	-0.52	-0.33	0.34	0.38	-0.46	0.24	0.38	-0.51	0.3	1.0	0.38
Inventory Turnover	-0.85	-0.39	0.86	-0.81	-0.27	0.67	-0.84	-0.39	-0.85	-0.21	0.42		0.33	-1.0	0.66	-0.81	-0.85	0.7	0.87	-0.8	0.79	0.87	-0.98	-0.32	0.46	0.88
Net Income Per Share	-0.77	0.04	0.04	-0.3	0.71	0.25	-0.77	0.04	-0.77	0.76	-0.02	0.33		-0.34	0.14	-0.27	-0.77	0.23	-0.11	-0.24	0.74	-0.12	-0.3	-0.46	0.0	-0.12
Days Of Inventory On Hand	0.85	0.37	-0.84	0.83	0.27	-0.69	0.85	0.37	0.85	0.21	-0.4	-1.0	-0.34		-0.62	0.83	0.85	-0.67	-0.88	0.82	-0.81	-0.87	0.97	0.3	-0.44	-0.89
Payables Turnover	-0.53	-0.37	0.9	-0.09	-0.02	0.18	-0.43	-0.37	-0.53	-0.01	0.4	0.66	0.14	-0.62		-0.15	-0.53	0.99	0.42	-0.11	0.23	0.42	-0.78	-0.47	0.42	0.48
Average Inventory	0.71	0.49	-0.46	0.94	0.46	-0.83	0.77	0.49	0.71	0.4	-0.52	-0.81	-0.27	0.83	-0.15		0.71	-0.19	-0.82	1.0	-0.83	-0.81	0.73	-0.08	-0.55	-0.79
Capex To Revenue	1.0	0.3	-0.6	0.69	-0.19	-0.59	0.99	0.3	1.0	-0.25	-0.33	-0.85	-0.77	0.85	-0.53	0.71		-0.6	-0.52	0.68	-0.93	-0.51	0.83	0.46	-0.37	-0.52
Cash Per Share	-0.6	-0.31	0.91	-0.16	0.04	0.2	-0.51	-0.31	-0.6	0.06	0.34	0.7	0.23	-0.67	0.99	-0.19	-0.6		0.45	-0.16	0.31	0.44	-0.81	-0.53	0.36	0.5
Pocfratio	-0.52	-0.35	0.77	-0.83	-0.65	0.68	-0.54	-0.35	-0.52	-0.6	0.38	0.87	-0.11	-0.88	0.42	-0.82	-0.52	0.45		-0.84	0.56	1.0	-0.82	-0.01	0.41	1.0
Interest Coverage	0.68	0.44	-0.44	0.96	0.47	-0.84	0.74	0.44	0.68	0.41	-0.46	-0.8	-0.24	0.82	-0.11	1.0	0.68	-0.16	-0.84		-0.82	-0.83	0.71	-0.1	-0.49	-0.81
Capex To Operating Cash Flow	-0.93	-0.22	0.4	-0.85	0.1	0.67	-0.97	-0.22	-0.93	0.17	0.24	0.79	0.74	-0.81	0.23	-0.83	-0.93	0.31	0.56	-0.82		0.55	-0.7	-0.3	0.28	0.54
Pfcf Ratio	-0.51	-0.35	0.77	-0.83	-0.66	0.68	-0.53	-0.35	-0.51	-0.61	0.38	0.87	-0.12	-0.87	0.42	-0.81	-0.51	0.44	1.0	-0.83	0.55		-0.82	0.0	0.41	1.0
Days Payables Outstanding	0.83	0.48	-0.92	0.68	0.26	-0.64	0.8	0.48	0.83	0.21	-0.51	-0.98	-0.3	0.97	-0.78	0.73	0.83	-0.81	-0.82	0.71	-0.7	-0.82		0.32	-0.54	-0.84
Income Quality	0.46	-0.32	-0.37	0.04	-0.53	0.41	0.41	-0.32	0.46	-0.55	0.3	-0.32	-0.46	0.3	-0.47	-0.08	0.46	-0.53	-0.01	-0.1	-0.3	0.0	0.32		0.28	-0.04
Roe	-0.37	-1.0	0.4	-0.24	-0.52	0.57	-0.34	-1.0	-0.37	-0.5	1.0	0.46	0.0	-0.44	0.42	-0.55	-0.37	0.36	0.41	-0.49	0.28	0.41	-0.54	0.28		0.41
Ev To Operating Cash Flow	-0.52	-0.35	0.81	-0.81	-0.64	0.66	-0.54	-0.35	-0.52	-0.59	0.38	0.88	-0.12	-0.89	0.48	-0.79	-0.52	0.5	1.0	-0.81	0.54	1.0	-0.84	-0.04	0.41

Click cells to compare fundamentals

Mink Therapeutics Account Relationship Matchups

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Mink Stock Analysis

When running Mink Therapeutics' price analysis, check to measure Mink Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mink Therapeutics is operating at the current time. Most of Mink Therapeutics' value examination focuses on studying past and present price action to predict the probability of Mink Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mink Therapeutics' price. Additionally, you may evaluate how the addition of Mink Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Price Book Value Ratio	Price Earnings To Growth Ratio
Days Of Payables Outstanding	Dividend Payout Ratio
Price To Operating Cash Flows Ratio	Price To Free Cash Flows Ratio
Pretax Profit Margin	Ebt Per Ebit
Operating Profit Margin	Effective Tax Rate
Company Equity Multiplier	Long Term Debt To Capitalization
Total Debt To Capitalization	Return On Capital Employed
Debt Equity Ratio	Ebit Per Revenue
Quick Ratio	Dividend Paid And Capex Coverage Ratio
Net Income Per E B T	Cash Ratio
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity	Operating Cycle
Cash Conversion Cycle

Mink Historical Financial Ratios

About Mink Financial Ratios Analysis

Mink Therapeutics Financial Ratios Chart

Price To Sales Ratio

Book Value Per Share

Ev To Sales

Inventory Turnover

Mink Therapeutics fundamentals Correlations

Mink Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Mink Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ev To Sales	+ 1.0	Price To Sales Ratio
Capex To Revenue	+ 1.0	Price To Sales Ratio
Pb Ratio	+ 1.0	Ptb Ratio
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Capex To Revenue	+ 1.0	Ev To Sales
Roe	+ 1.0	Roic

Days Of Inventory On Hand	- 1.0	Inventory Turnover
Roe	- 1.0	Pb Ratio
Roic	- 1.0	Pb Ratio
Roe	- 1.0	Ptb Ratio
Roic	- 1.0	Ptb Ratio
Days Payables Outstanding	- 0.98	Inventory Turnover